Rituximab
Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly
Explore 24 assets in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
University of Washington
Modality
monoclonal_antibody
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07097363CT.gov Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT06925555CT.gov Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS | — | Not Yet Recruiting | — | — | — |
NCT05583149CT.gov Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT05577364CT.gov Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients | — | Unknown | — | — | — |
NCT05202782CT.gov Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04799275CT.gov Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04705129CT.gov Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | — | Unknown | — | — | — |
NCT04231877CT.gov Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT04058470CT.gov Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | — | Unknown | — | — | — |
NCT03984448CT.gov Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | — | Active Not Recruiting | — | — | — |
Show 1 more trialShow fewer
NCT04181489CT.gov Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rituximab (this asset) | University of Washington | P2/3 | BB · 64 |
| Adriamycin | University of Washington | P2/3 | BB |
| Prednisone | University of Washington | P2/3 | BB |
| Cyclophosphamide | University of Washington | P2/3 | BB |
| Etoposide | University of Washington | P2/3 | B |
| Vincristine Sulfate | Northwestern University | P2/3 | B |
| (+)-Vincristine | Patrick C. Johnson, MD | P2 | B |
| Venetoclax | National Cancer Institute (NCI) | P2/3 | CCC |
| Azacitidine | National Cancer Institute (NCI) | P2/3 | CCC |
+22 more in the Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly cohort
Other indications for Rituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Grade III Lymphomatoid Granulomatosis | — | P2 | BBB · 74 |
| Testicular Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rituximab in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-epstein-barr-virus-positive-diffuse-large-b-cell-lymphoma-of-the-elderly
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →